A number of recent lectures and presentations by Drs Kazuhiro Sako (Astellas) and Sonja Skopp (Merck) have helped to raise the profile of the Pediatric Praziquantel Consortium and its efforts to create a new formulation for children younger than 6 years.

Regulators from many different African countries took part in a recent Pediatric Praziquantel Consortium meeting, held in Geneva in October. An intensive two-day agenda encompassed discussions of the entire regulatory approach for the Consortium’s new praziquantel pediatric formulation.

Regulators from many different African countries took part in a recent Pediatric Praziquantel Consortium meeting, held in Geneva in October. An intensive two-day agenda encompassed discussions of the entire regulatory approach for the Consortium’s new praziquantel pediatric formulation.

09-12-2014 As the holiday season arrives, we find ourselves reflecting on the past year – and on the inputs from everyone helping to shape the Pediatric Praziquantel Consortium.

We look at the experiences and viewpoints of three experts working with the Pediatric Praziquantel Consortium to help eliminate the genital form of schistosomiasis: Eyrun Kjetland, Jutta Reinhard-Rupp and Peter Hotez.

Prof. Jennifer Keiser of Swiss Tropical and Public Health Institute (Swiss TPH), partner at the Pediatric Praziquantel Consortium, received a prestigious ‘ERC Consolidator Grant’ from the European Research Council. 

The 2014 decision by the Japanese Global Health Innovative Technology Fund (GHIT Fund) to support the Pediatric Praziquantel Consortium was a major milestone. Its ¥186.5 million grant provides crucial support to the Consortium’s clinical development program, by providing funding for phase 1 clinical studies and taste tests.

As the Pediatric Praziquantel Consortium moves into the clinical trial stage, the Consortium Board has appointed Mrs. Kathleen Ford, Head of Global Clinical Operations at Merck Serono, as the new Chai

Dr. Otávio Pieri is a researcher at the Oswaldo Cruz Foundation, with a research focus on schistosomiasis. He explains what is happening in Brazil, and the importance of ensuring the right treatment for the preschool age group.

09-07-2014 The Pediatric Praziquantel Consortium partners are committed to enhancing awareness, and helping overall global efforts towards eliminating schistosomiasis. As part of this, they continue to organize, sponsor and participate in international congresses.

The Pediatric Praziquantel Consortium, launched in 2012 as an international non-profit public-private partnership, has announced that it has been awarded a prestigious research grant from the Japanese Global Health Innovative Technology (GHIT) Fund. 

Goal is to make treatment for schistosomiasis accessible to children under six years of age in endemic countries.

An international public-private partnership (PPP) was launched in July last year to develop a new pediatric formulation to combat schistosomiasis - commonly known as bilharzia - in preschool children.

A newly established international public-private partnership (PPP) between TI Pharma, Merck KGaA (Darmstadt, Germany), Astellas Pharma Inc. and the Swiss Tropical and Public Health Institute ("Swiss TPH") has been launched to develop a new pediatric formulation of praziquantel to combat schistosomiasis - commonly known as bilharzia - in preschool children.